Raymond James & Associates Raises Stock Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Raymond James & Associates lifted its position in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 1.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 207,228 shares of the life sciences company’s stock after buying an additional 2,903 shares during the period. Raymond James & Associates owned approximately 0.27% of Integra LifeSciences worth $9,025,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Swiss National Bank grew its position in shares of Integra LifeSciences by 0.9% in the 3rd quarter. Swiss National Bank now owns 161,994 shares of the life sciences company’s stock worth $6,187,000 after buying an additional 1,500 shares during the last quarter. Deerfield Management Company L.P. Series C purchased a new stake in Integra LifeSciences during the 3rd quarter worth approximately $43,034,000. Bridgefront Capital LLC grew its position in Integra LifeSciences by 299.3% during the 2nd quarter. Bridgefront Capital LLC now owns 16,348 shares of the life sciences company’s stock worth $672,000 after purchasing an additional 12,254 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in Integra LifeSciences during the 3rd quarter worth approximately $25,443,000. Finally, Vanguard Group Inc. grew its position in Integra LifeSciences by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 7,159,854 shares of the life sciences company’s stock worth $273,435,000 after purchasing an additional 72,294 shares during the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

Shares of NASDAQ IART opened at $34.00 on Friday. The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94. Integra LifeSciences Holdings Co. has a 12 month low of $33.24 and a 12 month high of $59.33. The company has a 50 day simple moving average of $38.54 and a two-hundred day simple moving average of $39.49. The stock has a market cap of $2.67 billion, a price-to-earnings ratio of 40.96, a PEG ratio of 1.02 and a beta of 1.12.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.01). Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The firm had revenue of $397.00 million during the quarter, compared to analyst estimates of $399.30 million. During the same quarter in the prior year, the firm earned $0.94 earnings per share. The business’s revenue for the quarter was down .3% on a year-over-year basis. As a group, analysts predict that Integra LifeSciences Holdings Co. will post 3.19 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on IART shares. Citigroup raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 target price on the stock in a research report on Wednesday. Truist Financial dropped their target price on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a research report on Friday, March 1st. JMP Securities dropped their target price on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a research report on Thursday, February 29th. Finally, StockNews.com downgraded shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Friday. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Integra LifeSciences presently has a consensus rating of “Hold” and an average target price of $44.89.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.